Browse CD74

Summary
SymbolCD74
NameCD74 molecule, major histocompatibility complex, class II invariant chain
Aliases HLA-DR-gamma; Ia-associated invariant chain; gamma chain of class II antigens; MHC HLA-DR gamma chain; DHLAG ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type II membrane protein Endoplasmic reticulum membrane. Golgi apparatus, trans-Golgi network. Endosome. Lysosome. Note=Transits through a number of intracellular compartments in the endocytic pathway. It can either undergo proteolysis or reach the cell membrane.
Domain PF09307 CLIP
PF08831 Class II MHC-associated invariant chain trimerisation domain
PF00086 Thyroglobulin type-1 repeat
Function

Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place. Serves as cell surface receptor for the cytokine MIF.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0001516 prostaglandin biosynthetic process
GO:0001776 leukocyte homeostasis
GO:0001782 B cell homeostasis
GO:0001783 B cell apoptotic process
GO:0001819 positive regulation of cytokine production
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0001961 positive regulation of cytokine-mediated signaling pathway
GO:0002250 adaptive immune response
GO:0002260 lymphocyte homeostasis
GO:0002274 myeloid leukocyte activation
GO:0002367 cytokine production involved in immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002468 dendritic cell antigen processing and presentation
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0002521 leukocyte differentiation
GO:0002577 regulation of antigen processing and presentation
GO:0002579 positive regulation of antigen processing and presentation
GO:0002604 regulation of dendritic cell antigen processing and presentation
GO:0002606 positive regulation of dendritic cell antigen processing and presentation
GO:0002683 negative regulation of immune system process
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002718 regulation of cytokine production involved in immune response
GO:0002720 positive regulation of cytokine production involved in immune response
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002792 negative regulation of peptide secretion
GO:0002828 regulation of type 2 immune response
GO:0002830 positive regulation of type 2 immune response
GO:0002901 mature B cell apoptotic process
GO:0002902 regulation of B cell apoptotic process
GO:0002903 negative regulation of B cell apoptotic process
GO:0002905 regulation of mature B cell apoptotic process
GO:0002906 negative regulation of mature B cell apoptotic process
GO:0006457 protein folding
GO:0006458 'de novo' protein folding
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006636 unsaturated fatty acid biosynthetic process
GO:0006690 icosanoid metabolic process
GO:0006692 prostanoid metabolic process
GO:0006693 prostaglandin metabolic process
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0010934 macrophage cytokine production
GO:0010935 regulation of macrophage cytokine production
GO:0015833 peptide transport
GO:0016053 organic acid biosynthetic process
GO:0016064 immunoglobulin mediated immune response
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019724 B cell mediated immunity
GO:0019882 antigen processing and presentation
GO:0019883 antigen processing and presentation of endogenous antigen
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0030335 positive regulation of cell migration
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0030888 regulation of B cell proliferation
GO:0030890 positive regulation of B cell proliferation
GO:0032103 positive regulation of response to external stimulus
GO:0032147 activation of protein kinase activity
GO:0032602 chemokine production
GO:0032642 regulation of chemokine production
GO:0032722 positive regulation of chemokine production
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033077 T cell differentiation in thymus
GO:0033559 unsaturated fatty acid metabolic process
GO:0033674 positive regulation of kinase activity
GO:0035691 macrophage migration inhibitory factor signaling pathway
GO:0040017 positive regulation of locomotion
GO:0042092 type 2 immune response
GO:0042100 B cell proliferation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042116 macrophage activation
GO:0042770 signal transduction in response to DNA damage
GO:0042771 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
GO:0042886 amide transport
GO:0043030 regulation of macrophage activation
GO:0043368 positive T cell selection
GO:0043383 negative T cell selection
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043516 regulation of DNA damage response, signal transduction by p53 class mediator
GO:0043518 negative regulation of DNA damage response, signal transduction by p53 class mediator
GO:0044283 small molecule biosynthetic process
GO:0045058 T cell selection
GO:0045059 positive thymic T cell selection
GO:0045060 negative thymic T cell selection
GO:0045061 thymic T cell selection
GO:0045580 regulation of T cell differentiation
GO:0045581 negative regulation of T cell differentiation
GO:0045582 positive regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045620 negative regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045785 positive regulation of cell adhesion
GO:0045860 positive regulation of protein kinase activity
GO:0046394 carboxylic acid biosynthetic process
GO:0046456 icosanoid biosynthetic process
GO:0046457 prostanoid biosynthetic process
GO:0046651 lymphocyte proliferation
GO:0048002 antigen processing and presentation of peptide antigen
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048872 homeostasis of number of cells
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050863 regulation of T cell activation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050870 positive regulation of T cell activation
GO:0050871 positive regulation of B cell activation
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051084 'de novo' posttranslational protein folding
GO:0051085 chaperone mediated protein folding requiring cofactor
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051272 positive regulation of cellular component movement
GO:0060326 cell chemotaxis
GO:0060759 regulation of response to cytokine stimulus
GO:0060760 positive regulation of response to cytokine stimulus
GO:0060907 positive regulation of macrophage cytokine production
GO:0061077 chaperone-mediated protein folding
GO:0061081 positive regulation of myeloid leukocyte cytokine production involved in immune response
GO:0061082 myeloid leukocyte cytokine production
GO:0070227 lymphocyte apoptotic process
GO:0070228 regulation of lymphocyte apoptotic process
GO:0070229 negative regulation of lymphocyte apoptotic process
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071593 lymphocyte aggregation
GO:0071594 thymocyte aggregation
GO:0071621 granulocyte chemotaxis
GO:0071622 regulation of granulocyte chemotaxis
GO:0071624 positive regulation of granulocyte chemotaxis
GO:0071887 leukocyte apoptotic process
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072330 monocarboxylic acid biosynthetic process
GO:0072331 signal transduction by p53 class mediator
GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator
GO:0072567 chemokine (C-X-C motif) ligand 2 production
GO:0090022 regulation of neutrophil chemotaxis
GO:0090023 positive regulation of neutrophil chemotaxis
GO:0090087 regulation of peptide transport
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1901797 negative regulation of signal transduction by p53 class mediator
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1902165 regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
GO:1902166 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902253 regulation of intrinsic apoptotic signaling pathway by p53 class mediator
GO:1902254 negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator
GO:1902532 negative regulation of intracellular signal transduction
GO:1902622 regulation of neutrophil migration
GO:1902624 positive regulation of neutrophil migration
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1990266 neutrophil migration
GO:2000106 regulation of leukocyte apoptotic process
GO:2000107 negative regulation of leukocyte apoptotic process
GO:2000147 positive regulation of cell motility
GO:2000341 regulation of chemokine (C-X-C motif) ligand 2 production
GO:2000343 positive regulation of chemokine (C-X-C motif) ligand 2 production
GO:2001020 regulation of response to DNA damage stimulus
GO:2001021 negative regulation of response to DNA damage stimulus
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function GO:0001540 beta-amyloid binding
GO:0003823 antigen binding
GO:0004896 cytokine receptor activity
GO:0019955 cytokine binding
GO:0023023 MHC protein complex binding
GO:0023026 MHC class II protein complex binding
GO:0033218 amide binding
GO:0035718 macrophage migration inhibitory factor binding
GO:0042277 peptide binding
GO:0042287 MHC protein binding
GO:0042289 MHC class II protein binding
GO:0042658 MHC class II protein binding, via antigen binding groove
GO:0044183 protein binding involved in protein folding
GO:0050998 nitric-oxide synthase binding
Cellular Component GO:0005765 lysosomal membrane
GO:0005770 late endosome
GO:0005771 multivesicular body
GO:0005775 vacuolar lumen
GO:0005802 trans-Golgi network
GO:0009897 external side of plasma membrane
GO:0012507 ER to Golgi transport vesicle membrane
GO:0030133 transport vesicle
GO:0030134 ER to Golgi transport vesicle
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030176 integral component of endoplasmic reticulum membrane
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030665 clathrin-coated vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030669 clathrin-coated endocytic vesicle membrane
GO:0031227 intrinsic component of endoplasmic reticulum membrane
GO:0031984 organelle subcompartment
GO:0032588 trans-Golgi network membrane
GO:0035692 macrophage migration inhibitory factor receptor complex
GO:0035693 NOS2-CD74 complex
GO:0042611 MHC protein complex
GO:0042613 MHC class II protein complex
GO:0043202 lysosomal lumen
GO:0043235 receptor complex
GO:0045334 clathrin-coated endocytic vesicle
GO:0071556 integral component of lumenal side of endoplasmic reticulum membrane
GO:0098552 side of membrane
GO:0098553 lumenal side of endoplasmic reticulum membrane
GO:0098791 Golgi subcompartment
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04612 Antigen processing and presentation
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-2132295: MHC class II antigen presentation
Summary
SymbolCD74
NameCD74 molecule, major histocompatibility complex, class II invariant chain
Aliases HLA-DR-gamma; Ia-associated invariant chain; gamma chain of class II antigens; MHC HLA-DR gamma chain; DHLAG ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD74 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD74 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26500140Diffuse Large B-Cell LymphomaPromote immunityFOXP1 knockdown in ABC-DLBCL cells led to increased cell-surface expression of HLA-DRA and CD74. We propose that FOXP1 represents a novel regulator of genes targeted by the class II MHC transactivator CIITA (MHC II and CD74) and therapeutically targeting the FOXP1 pathway may improve antigen presentation and immune surveillance in high-risk DLBCL patients.
27157615Brain NeoplasmInhibit immunityThe inhibition of MIF signaling or its receptor CD74 promotes IFN-γ release and amplifies tumor death either through pharmacological inhibition or through siRNA-mediated knockdown.
Summary
SymbolCD74
NameCD74 molecule, major histocompatibility complex, class II invariant chain
Aliases HLA-DR-gamma; Ia-associated invariant chain; gamma chain of class II antigens; MHC HLA-DR gamma chain; DHLAG ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD74 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD74
NameCD74 molecule, major histocompatibility complex, class II invariant chain
Aliases HLA-DR-gamma; Ia-associated invariant chain; gamma chain of class II antigens; MHC HLA-DR gamma chain; DHLAG ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD74 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3630.489
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3070.948
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4050.906
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8870.166
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1550.957
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.8230.644
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6160.363
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9860.718
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1050.974
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4520.699
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3730.819
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.130.461
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD74 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD74
NameCD74 molecule, major histocompatibility complex, class II invariant chain
Aliases HLA-DR-gamma; Ia-associated invariant chain; gamma chain of class II antigens; MHC HLA-DR gamma chain; DHLAG ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD74. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD74
NameCD74 molecule, major histocompatibility complex, class II invariant chain
Aliases HLA-DR-gamma; Ia-associated invariant chain; gamma chain of class II antigens; MHC HLA-DR gamma chain; DHLAG ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD74. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD74.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD74
NameCD74 molecule, major histocompatibility complex, class II invariant chain
Aliases HLA-DR-gamma; Ia-associated invariant chain; gamma chain of class II antigens; MHC HLA-DR gamma chain; DHLAG ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD74. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD74
NameCD74 molecule, major histocompatibility complex, class II invariant chain
Aliases HLA-DR-gamma; Ia-associated invariant chain; gamma chain of class II antigens; MHC HLA-DR gamma chain; DHLAG ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD74 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD74
NameCD74 molecule, major histocompatibility complex, class II invariant chain
Aliases HLA-DR-gamma; Ia-associated invariant chain; gamma chain of class II antigens; MHC HLA-DR gamma chain; DHLAG ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD74 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD74
NameCD74 molecule, major histocompatibility complex, class II invariant chain
Aliases HLA-DR-gamma; Ia-associated invariant chain; gamma chain of class II antigens; MHC HLA-DR gamma chain; DHLAG ......
Chromosomal Location5q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD74 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.